Selective effects of clofibrate on alkaline phosphatase isoenzymes in serum.
Administration of clofibrate to both hyperlipidaemic patients and normolipidaemic subjects produced a significant decrease, averaging 22%, in serum alkaline phosphatase activity. Quantitative isoenzyme analysis showed that this change was entirely attributable to an average reduction of 39% in the activity of liver alkaline phosphatase, and that no significant change in the bone isoenzyme occurred. An accompanying fall in serum gamma-glutamyltransferase activity was seen in some subjects but this change was not statistically significant in the group as a whole.
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood*; D001842:Bone and Bones / Q000201:enzymology; D002994:Clofibrate; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000201:enzymology*; D007527:Isoenzymes / Q000097:blood*; D008099:Liver / Q000201:enzymology; D008297:Male; D005723:gamma-Glutamyltransferase / Q000097:blood
D007527:Isoenzymes; D005723:gamma-Glutamyltransferase; D000469:Alkaline Phosphatase; D002994:Clofibrate